JP2010514831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514831A5 JP2010514831A5 JP2009544450A JP2009544450A JP2010514831A5 JP 2010514831 A5 JP2010514831 A5 JP 2010514831A5 JP 2009544450 A JP2009544450 A JP 2009544450A JP 2009544450 A JP2009544450 A JP 2009544450A JP 2010514831 A5 JP2010514831 A5 JP 2010514831A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- table below
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 37
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- -1 2-hydroxy-1-methylethyl Chemical group 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0700125A GB0700125D0 (en) | 2007-01-04 | 2007-01-04 | GPCR agonists |
| GB0708746A GB0708746D0 (en) | 2007-05-08 | 2007-05-08 | GPCR agonists |
| GB0719763A GB0719763D0 (en) | 2007-10-10 | 2007-10-10 | GPCR agonists |
| PCT/GB2008/050013 WO2008081207A1 (en) | 2007-01-04 | 2008-01-04 | Piperidine gpcr agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010514831A JP2010514831A (ja) | 2010-05-06 |
| JP2010514831A5 true JP2010514831A5 (enExample) | 2011-02-24 |
Family
ID=39199058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544450A Pending JP2010514831A (ja) | 2007-01-04 | 2008-01-04 | ピペリジンｇｐｃｒアゴニスト |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20100105732A1 (enExample) |
| EP (2) | EP2114935B1 (enExample) |
| JP (1) | JP2010514831A (enExample) |
| AR (1) | AR064735A1 (enExample) |
| AT (1) | ATE517103T1 (enExample) |
| BR (1) | BRPI0806500A2 (enExample) |
| CA (1) | CA2674455A1 (enExample) |
| CL (1) | CL2008000018A1 (enExample) |
| CY (1) | CY1112474T1 (enExample) |
| DK (1) | DK2114935T3 (enExample) |
| EA (1) | EA015130B1 (enExample) |
| HR (1) | HRP20110750T1 (enExample) |
| PE (1) | PE20081659A1 (enExample) |
| PL (1) | PL2114935T3 (enExample) |
| PT (1) | PT2114935E (enExample) |
| RS (1) | RS51943B (enExample) |
| SA (1) | SA08280757B1 (enExample) |
| SI (1) | SI2114935T1 (enExample) |
| TW (1) | TW200835482A (enExample) |
| WO (1) | WO2008081207A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070091038A (ko) * | 2004-12-24 | 2007-09-06 | 프로시디온 리미티드 | Ｇ-단백질 결합 수용체(ｇｐｒ116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도 |
| BRPI0613505A2 (pt) * | 2005-06-30 | 2011-01-11 | Prosidion Ltd | agonistas de gpcr |
| CL2008000017A1 (es) * | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| EP2200609A1 (en) | 2007-09-10 | 2010-06-30 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
| CN101868452B (zh) | 2007-10-10 | 2014-08-06 | 诺华股份有限公司 | 螺环吡咯烷类与其对抗hcv和hiv感染的应用 |
| GB0812648D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0812641D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0812649D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| WO2010084512A1 (en) * | 2008-12-24 | 2010-07-29 | Cadila Healthcare Limited | Novel oxime derivatives |
| GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904285D0 (en) * | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| US8293729B2 (en) | 2009-06-24 | 2012-10-23 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| US8481731B2 (en) | 2009-06-24 | 2013-07-09 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
| GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
| WO2012170867A1 (en) | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN104610393A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一类含氨基葡萄糖和卤代吡啶结构化合物及其用途 |
| CN104610390A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一种含氨基葡萄糖和腈基吡啶结构的gpr119激动剂及其用途 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
| US5252586A (en) * | 1990-09-28 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| DE4222565A1 (de) * | 1992-07-09 | 1994-01-13 | Hoechst Ag | Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen |
| US6100042A (en) * | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
| DE4311968A1 (de) * | 1993-04-10 | 1994-10-20 | Hoechst Ag | Smektische Flüssigkristallmischung |
| DE4311967A1 (de) * | 1993-04-10 | 1994-10-13 | Hoechst Ag | Smektische Flüssigkristallmischung |
| US5338738A (en) * | 1993-04-19 | 1994-08-16 | Bristol-Myers Squibb Company | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines |
| FR2705346B1 (fr) * | 1993-05-18 | 1995-08-11 | Union Pharma Scient Appl | Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques . |
| JPH11513382A (ja) * | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| CA2262569A1 (en) | 1996-08-09 | 1998-02-19 | Norihito Ohi | Benzopiperidine derivatives |
| GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
| WO2000012705A2 (en) | 1998-09-01 | 2000-03-09 | Basf Aktiengesellschaft | Methods for improving the function of heterologous g protein-coupled receptors |
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| CN1206220C (zh) * | 2000-11-21 | 2005-06-15 | 三菱化学株式会社 | 生产2－(4－吡啶基)乙硫醇的方法 |
| FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
| FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
| JP2005507875A (ja) | 2001-08-31 | 2005-03-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なピラゾール類似体 |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| KR100903760B1 (ko) | 2001-09-21 | 2009-06-19 | 솔베이 파마슈티칼스 비. 브이 | Ｃｂ1-길항 작용을 가지는 신규한4,5-디하이드로-1ｈ-피라졸 유도체 |
| HUP0402113A3 (en) | 2001-09-21 | 2012-05-29 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof |
| FR2831883B1 (fr) | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
| SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| FR2833842B1 (fr) | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
| AU2003209388A1 (en) | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| AU2003219934A1 (en) | 2002-03-06 | 2003-09-22 | Merck And Co., Inc. | Method of treatment or prevention of obesity |
| JP3813152B2 (ja) | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
| JP2005528366A (ja) | 2002-03-26 | 2005-09-22 | メルク エンド カムパニー インコーポレーテッド | カンナビノイド受容体モジュレータとしてのスピロ環式アミド |
| ES2192494B1 (es) | 2002-03-27 | 2005-02-16 | Consejo Superior De Investigaciones Cientificas | Derivados de 1,2,4-triazol con propiedades cannabinoides. |
| WO2003082191A2 (en) | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| CA2480856A1 (en) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
| FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
| FR2838438A1 (fr) | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
| US7667053B2 (en) | 2002-04-12 | 2010-02-23 | Merck & Co., Inc. | Bicyclic amides |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| KR100741231B1 (ko) | 2002-07-29 | 2007-07-19 | 에프. 호프만-라 로슈 아게 | 신규 벤조다이옥솔 |
| US7091216B2 (en) | 2002-08-02 | 2006-08-15 | Merck & Co., Inc. | Substituted furo[2,3-b]pyridine derivatives |
| AU2003296895A1 (en) | 2002-08-20 | 2004-05-04 | The Regents Of The University Of California | Combination therapy for controlling appetites |
| HRP20050053A2 (en) | 2002-09-19 | 2005-04-30 | Solvay Pharmaceuticals B.V. | 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
| CA2499497A1 (en) | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
| JP2006506366A (ja) | 2002-10-18 | 2006-02-23 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドおよびその使用方法 |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| AU2003300967B2 (en) | 2002-12-19 | 2009-05-28 | Merck Sharp & Dohme Corp. | Substituted amides |
| GB0230087D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| PL378244A1 (pl) | 2003-01-02 | 2006-03-20 | F. Hoffmann-La Roche Ag | Pirolilotiazole i ich zastosowanie jako odwrotnych agonistów receptora CB 1 |
| CN101012193A (zh) | 2003-01-02 | 2007-08-08 | 霍夫曼-拉罗奇有限公司 | 新cb 1受体反激动剂 |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| EP1597259B1 (de) | 2003-02-13 | 2008-04-30 | Sanofi-Aventis Deutschland GmbH | Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| BRPI0407507A (pt) | 2003-02-13 | 2006-02-14 | Aventis Pharma Gmbh | derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona, processos para sua preparação de sua aplicação como medicamento |
| US20040167188A1 (en) * | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
| US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
| WO2004078261A1 (en) | 2003-03-07 | 2004-09-16 | The University Court Of The University Of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| AR045496A1 (es) * | 2003-08-29 | 2005-11-02 | Schering Corp | Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados |
| WO2005061489A1 (en) | 2003-12-24 | 2005-07-07 | Prosidion Limited | Heterocyclic derivatives as gpcr receptor agonists |
| US8193359B2 (en) | 2004-12-24 | 2012-06-05 | Prosidion Limited | G-protein coupled receptor agonists |
| KR20070091038A (ko) * | 2004-12-24 | 2007-09-06 | 프로시디온 리미티드 | Ｇ-단백질 결합 수용체(ｇｐｒ116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도 |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| NZ564758A (en) | 2005-06-30 | 2011-03-31 | Prosidion Ltd | G-protein coupled receptor agonists |
| US20090221644A1 (en) | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
| EP1907383A1 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
| BRPI0613505A2 (pt) * | 2005-06-30 | 2011-01-11 | Prosidion Ltd | agonistas de gpcr |
| JP2009532453A (ja) * | 2006-04-06 | 2009-09-10 | プロシディオン・リミテッド | ヘテロサイクリックｇｐｃｒアゴニスト |
| ES2374952T3 (es) * | 2006-12-06 | 2012-02-23 | Glaxosmithkline Llc | Compuestos bicíclicos y uso como antidiabéticos. |
| CL2008000017A1 (es) * | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
-
2008
- 2008-01-03 CL CL200800018A patent/CL2008000018A1/es unknown
- 2008-01-03 AR ARP080100017A patent/AR064735A1/es unknown
- 2008-01-03 PE PE2008000084A patent/PE20081659A1/es not_active Application Discontinuation
- 2008-01-04 PT PT08702096T patent/PT2114935E/pt unknown
- 2008-01-04 CA CA002674455A patent/CA2674455A1/en not_active Abandoned
- 2008-01-04 WO PCT/GB2008/050013 patent/WO2008081207A1/en not_active Ceased
- 2008-01-04 PL PL08702096T patent/PL2114935T3/pl unknown
- 2008-01-04 JP JP2009544450A patent/JP2010514831A/ja active Pending
- 2008-01-04 EP EP08702096A patent/EP2114935B1/en active Active
- 2008-01-04 DK DK08702096.2T patent/DK2114935T3/da active
- 2008-01-04 EP EP11169308A patent/EP2377864A1/en not_active Withdrawn
- 2008-01-04 EA EA200900880A patent/EA015130B1/ru not_active IP Right Cessation
- 2008-01-04 TW TW097100416A patent/TW200835482A/zh unknown
- 2008-01-04 SI SI200830401T patent/SI2114935T1/sl unknown
- 2008-01-04 RS RS20110448A patent/RS51943B/sr unknown
- 2008-01-04 AT AT08702096T patent/ATE517103T1/de active
- 2008-01-04 HR HR20110750T patent/HRP20110750T1/hr unknown
- 2008-01-04 US US12/522,023 patent/US20100105732A1/en not_active Abandoned
- 2008-01-04 BR BRPI0806500-4A2A patent/BRPI0806500A2/pt not_active IP Right Cessation
- 2008-01-05 SA SA8280757A patent/SA08280757B1/ar unknown
-
2011
- 2011-10-17 CY CY20111100985T patent/CY1112474T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514831A5 (enExample) | ||
| JP2010514829A5 (enExample) | ||
| JP2010514832A5 (enExample) | ||
| JP2011527332A5 (enExample) | ||
| JP2011527333A5 (enExample) | ||
| JP2011500658A5 (enExample) | ||
| JP2011527331A5 (enExample) | ||
| RU2470016C2 (ru) | Производное бипиразола | |
| JP2011500659A5 (enExample) | ||
| JP2011522897A5 (enExample) | ||
| JP2011527334A5 (enExample) | ||
| JP2011527335A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2008525416A5 (enExample) | ||
| JP2010514828A5 (enExample) | ||
| JP2006143751A5 (enExample) | ||
| JP2009533410A5 (enExample) | ||
| JP2008007519A5 (enExample) | ||
| RU2009135016A (ru) | Твердые формы, содержащие (-)-о-десметилвенлафаксин, и их применения | |
| WO2007060140A3 (en) | Inhibitors of diacyglycerol acyltransferase (dgat) | |
| JP2007500720A5 (enExample) | ||
| JP2012512907A5 (enExample) | ||
| IL187005A0 (en) | Diacylglycerol acyltransferase inhibitors | |
| JP2008533007A5 (enExample) | ||
| JP2010527980A5 (enExample) |